The Russian Parliament (State Duma) will consider a draft of a new federal law that will establish a state monopoly on the production of drugs in Russia, reports The Pharma Letter’s local correspondent.
To date, the draft of the law has already been designed and registered in the State Duma, while its official consideration and possible approval may take place already in the middle of April of the current year.
According to Maxim Shchepinov, deputy chairman of the Committee on Labor and Veterans Affairs of the State Duma, who became one of the initiators of the new law, its adoption is very important amid the existing Western sanctions against Russia.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze